Maxalt
Product Images NDC 16590-461

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Maxalt (NDC 16590-461). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Structural Formula (580e55c2 F9b7 4212 98b7 Cee54f55d309 01)

FDA Label Image

Image Of Figure 1 (580e55c2 F9b7 4212 98b7 Cee54f55d309 02)

Image Of Figure 1 (580e55c2 F9b7 4212 98b7 Cee54f55d309 02)
The text describes a graph (Figure 1) that displays the estimated probability of headache response over time after taking either a medication called izairptan or a placebo. The graph uses the Kapian-Meier method and shows that the probability of response increases over time. The data used for the graph comes from four outpatient trials and includes patients who did not respond to treatment within 2 hours.*
FDA Label Image

Image Of Figure 2 (580e55c2 F9b7 4212 98b7 Cee54f55d309 03)

FDA Label Image

Image Of Figure 3 (580e55c2 F9b7 4212 98b7 Cee54f55d309 04)

Image Of Figure 3 (580e55c2 F9b7 4212 98b7 Cee54f55d309 04)
The text appears to be a description of a medical study that compares the effectiveness of MAXALT-MLT to placebo in treating headaches. The study includes graphs of the probability of obtaining headache relief over time. Patients who did not achieve relief within 2 hours or those who received additional treatment were censored in the study.*
FDA Label Image

Image Of Figure 4 (580e55c2 F9b7 4212 98b7 Cee54f55d309 05)

Image Of Figure 4 (580e55c2 F9b7 4212 98b7 Cee54f55d309 05)
This Kaplan-Meier plot is based on data obtained in 2 placebo-controlled outpatient clinical trials (Studies 1 and 2), for the treatment of headache with EsinatsdProtatity and Remstaton o Fescue. The plot includes both patients who had headache response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose. Data was censored at 24 hours for patients not using additional treatments.*
FDA Label Image

Label Image 10mg (Maxalt 10mg Label 461)

FDA Label Image

Label Image (Maxalt mLt 5mg 144)

Label Image (Maxalt mLt 5mg 144)
This is a sample medication called "STAT R USA Gtnsedte" produced by Merek & Co, Inc. Each tablet contains 14.53mg of Rizatriptan Benzoate equivalent to 5mg of rizatriptan. It warns about the possibility of drowsiness and dizziness and the risk of intensification with alcohol. The lot number is 10087060, and it should be discarded after 03/13 in the year 2010. The remaining text is not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.